115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
    Meeting Abstract

    Chia, S.; Neven, P.; Ciruelos, E. M.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Prat, A.; Park, Y. H.; Juric, D.; Turner, N. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • State mandatory paid medical leave policies and survival among adults with cancer in the US
    Meeting Abstract

    Barnes, J. M.; Chino, F.; Johnson, K. J.; Zheng, Z.; Han, X.; Yabroff, R.; Johnston, K. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Sharma, M.; Berz, D.; Caswell-Jin, J. L.; Spira, A. I.; Fulgar, G. A.; Densel, M.; Rana, N.; Sperry, S.; Warner, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment
    Meeting Abstract

    Wander, S. A.; Weipert, C. M.; Liao, J.; Safonov, A.; Zhang, N.; Bardia, A.; Razavi, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
    Meeting Abstract

    Modi, S.; Niikura, N.; Yamashita, T.; Jacot, W.; Sohn, J.; Tokunaga, E.; Vidal, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial
    Meeting Abstract

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Iwata, H.; Jhaveri, K. L.; Loibl, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Do HER2 low tumors have a distinct clinicopathologic phenotype?
    Meeting Abstract

    Polidorio, N.; Veeravalli, S. S.; Montagna, G.; Le, T.; Morrow, M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
    Meeting Abstract

    Tolaney, S. M.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Gómez Pardo, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03
    Meeting Abstract

    Krop, I. E.; Wildiers, H.; Hurvitz, S. A.; Cortes, J.; Im, S. A.; Iwata, H.; Andre, F.; Saura, C.; Modi, S.; Kim, S. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save